We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
RNA category is based on mRNA expression levels in the analyzed samples (RNA assay description). The categories include: tissue/cell line enriched, group enriched, tissue/cell line enhanced, expressed in all, mixed and not detected. RNA category is calculated separately for The Cancer Genome Atlas (TCGA) data from cancer tissues and internally generated Human Protein Atlas (HPA) data from normal tissues and cell lines.
TCGA (cancer tissue):
Expressed in all
HPA (cell line):
Expressed in all
HPA (normal tissue):
Tissue enhanced (testis)
Protein evidencei
Protein evidence scores are generated from several independent sources and are classified as evidence at i) protein level, ii) transcript level, iii) no evidence, or iv) not available.
Evidence at protein level
Protein expression normal tissuei
A summary of the overall protein expression pattern across the analyzed normal tissues. The summary is based on knowledge-based annotation.
"Estimation of protein expression could not be performed. View primary data." is shown for genes analyzed with a knowledge-based approach where available RNA-seq and gene/protein characterization data has been evaluated as not sufficient in combination with immunohistochemistry data to yield a reliable estimation of the protein expression profile.
Standardized explanatory sentences with additional information required for full understanding of the knowledge-based expression profile.
Antibody staining mainly not consistent with RNA expression data.
Reliability score - normal tissuesi
Reliability score (score description), divided into Enhanced, Supported, Approved, or Uncertain, is evaluated in normal tissues and based on consistency between antibody staining pattern, available RNA-Seq and gene/protein characterization data, as well as similarity between independent antibodies targeting the same protein.
Kaplan-Meier plots for all cancers where high expression of this gene has significant (p<0.001) association with patient survival are shown in this summary. Whether the prognosis is favourable or unfavourable is indicated in brackets. Each Kaplan-Meier plot is clickable and redirects to a detailed page that includes individual expression and survival data for patients with the selected cancer.
RNA expression overview shows RNA-seq data from The Cancer Genome Atlas (TCGA).
TCGA dataseti
RNA-seq data in 17 cancer types are reported as median FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA). RNA cancer tissue category is calculated based on mRNA expression levels across all 17 cancer tissues and include: cancer tissue enriched, cancer group enriched, cancer tissue enhanced, expressed in all, mixed and not detected. To access cancer specific RNA and prognostic data, click on the cancer name. The cancer types are color-coded according to which type of normal organ the cancer originates from.
Antibody staining in 20 different cancers is summarized by a selection of four standard cancer tissue samples representative of the overall staining pattern. From left: colorectal cancer, breast cancer, prostate cancer and lung cancer. An additional fifth image can be added as a complement. The assay and annotation is described here. Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
For each cancer, color-coded bars indicate the percentage of patients (maximum 12 patients) with high and medium protein expression level. The cancer types are color-coded according to which type of normal organ the cancer originates from. Low or not detected protein expression results in a white bar. Mouse-over function shows details about expression level and normal tissue of origin. The images and annotations can be accessed by clicking on the cancer name or protein expression bar. If more than one antibody is analyzed, the tabs at the top of the staining summary section can be used to toggle between the different antibodies.
Weak to moderate nuclear membranous or nuclear positivity was observed in most cancer tissues. Prostate cancers displayed weak to moderate cytoplasmic immunoreactivity, with a granular pattern. Lymphomas, carcinoids, gliomas, colorectal, testicular and stomach cancers were generally negative.
Most cancer tissues displayed moderate nuclear and cytoplasmic positivity. A few melanomas along with occasional adenocarcinomas of cervix and endometrial cancers were strongly stained.
GENE INFORMATIONi
Gene information from Ensembl and Entrez, as well as links to available gene identifiers are displayed here. Information was retrieved from Ensembl if not indicated otherwise.
Gene name
PLK1 (HGNC Symbol)
Synonyms
PLK
Description
Polo like kinase 1 (HGNC Symbol)
Entrez gene summary
The Ser/Thr protein kinase encoded by this gene belongs to the CDC5/Polo subfamily. It is highly expressed during mitosis and elevated levels are found in many different types of cancer. Depletion of this protein in cancer cells dramatically inhibited cell proliferation and induced apoptosis; hence, it is a target for cancer therapy. [provided by RefSeq, Sep 2015]
The protein browser displays the antigen location on the target protein(s) and the features of the target protein. The tabs at the top of the protein view section can be used to switch between the different splice variants to which an antigen has been mapped.
At the top of the view, the position of the antigen (identified by the corresponding HPA identifier) is shown as a green bar. A yellow triangle on the bar indicates a <100% sequence identity to the protein target.
Under the antigens, the maximum percent sequence identity of the protein to all other proteins from other human genes is displayed, using a sliding window of 10 aa residues (HsID 10) or 50 aa residues (HsID 50). The region with the lowest possible identity is always selected for antigen design, with a maximum identity of 60% allowed for designing a single-target antigen (read more).
The curve in blue displays the predicted antigenicity i.e. the tendency for different regions of the protein to generate an immune response, with peak regions being predicted to be more antigenic.The curve shows average values based on a sliding window approach using an in-house propensity scale. (read more).
If a signal peptide is predicted by a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius (turquoise) and/or transmembrane regions (orange) are predicted by MDM, these are displayed.
Low complexity regions are shown in yellow and InterPro regions in green. Common (purple) and unique (grey) regions between different splice variants of the gene are also displayed (read more), and at the bottom of the protein view is the protein scale.
PLK1-001
PLK1-007
PLK1-008
PROTEIN INFORMATIONi
The protein information section displays alternative protein-coding transcripts (splice variants) encoded by this gene according to the Ensembl database.
The ENSP identifier links to the Ensembl website protein summary, while the ENST identifier links to the Ensembl website transcript summary for the selected splice variant. The data in the UniProt column can be expanded to show links to all matching UniProt identifiers for this protein.
The protein classes assigned to this protein are shown if expanding the data in the protein class column. Parent protein classes are in bold font and subclasses are listed under the parent class.
The Gene Ontology terms assigned to this protein are listed if expanding the Gene ontology column. The length of the protein (amino acid residues according to Ensembl), molecular mass (kDalton), predicted signal peptide (according to a majority of the signal peptide predictors SPOCTOPUS, SignalP 4.0, and Phobius) and the number of predicted transmembrane region(s) (according to MDM) are also reported.
Enzymes ENZYME proteins Transferases Kinases MEMSAT-SVM predicted membrane proteins SPOCTOPUS predicted membrane proteins Predicted intracellular proteins Cancer-related genes Candidate cancer biomarkers Disease related genes Potential drug targets Protein evidence (Kim et al 2014) Protein evidence (Ezkurdia et al 2014)
Show all
GO:0000070 [mitotic sister chromatid segregation] GO:0000086 [G2/M transition of mitotic cell cycle] GO:0000122 [negative regulation of transcription from RNA polymerase II promoter] GO:0000166 [nucleotide binding] GO:0000281 [mitotic cytokinesis] GO:0000775 [chromosome, centromeric region] GO:0000776 [kinetochore] GO:0000777 [condensed chromosome kinetochore] GO:0000780 [condensed nuclear chromosome, centromeric region] GO:0000785 [chromatin] GO:0000795 [synaptonemal complex] GO:0000910 [cytokinesis] GO:0000922 [spindle pole] GO:0000942 [condensed nuclear chromosome outer kinetochore] GO:0001578 [microtubule bundle formation] GO:0004672 [protein kinase activity] GO:0004674 [protein serine/threonine kinase activity] GO:0005515 [protein binding] GO:0005524 [ATP binding] GO:0005634 [nucleus] GO:0005654 [nucleoplasm] GO:0005694 [chromosome] GO:0005737 [cytoplasm] GO:0005813 [centrosome] GO:0005815 [microtubule organizing center] GO:0005819 [spindle] GO:0005829 [cytosol] GO:0005856 [cytoskeleton] GO:0005876 [spindle microtubule] GO:0006468 [protein phosphorylation] GO:0007049 [cell cycle] GO:0007062 [sister chromatid cohesion] GO:0007067 [mitotic nuclear division] GO:0007077 [mitotic nuclear envelope disassembly] GO:0007094 [mitotic spindle assembly checkpoint] GO:0007346 [regulation of mitotic cell cycle] GO:0008017 [microtubule binding] GO:0008283 [cell proliferation] GO:0010800 [positive regulation of peptidyl-threonine phosphorylation] GO:0010997 [anaphase-promoting complex binding] GO:0015630 [microtubule cytoskeleton] GO:0016301 [kinase activity] GO:0016310 [phosphorylation] GO:0016321 [female meiosis chromosome segregation] GO:0016567 [protein ubiquitination] GO:0016740 [transferase activity] GO:0018105 [peptidyl-serine phosphorylation] GO:0019901 [protein kinase binding] GO:0030071 [regulation of mitotic metaphase/anaphase transition] GO:0030496 [midbody] GO:0031145 [anaphase-promoting complex-dependent catabolic process] GO:0031572 [G2 DNA damage checkpoint] GO:0031648 [protein destabilization] GO:0032436 [positive regulation of proteasomal ubiquitin-dependent protein catabolic process] GO:0042787 [protein ubiquitination involved in ubiquitin-dependent protein catabolic process] GO:0043066 [negative regulation of apoptotic process] GO:0043393 [regulation of protein binding] GO:0045143 [homologous chromosome segregation] GO:0045184 [establishment of protein localization] GO:0045736 [negative regulation of cyclin-dependent protein serine/threonine kinase activity] GO:0045862 [positive regulation of proteolysis] GO:0051081 [nuclear envelope disassembly] GO:0051233 [spindle midzone] GO:0051297 [centrosome organization] GO:0051301 [cell division] GO:0051437 [positive regulation of ubiquitin-protein ligase activity involved in regulation of mitotic cell cycle transition] GO:0051439 [regulation of ubiquitin-protein ligase activity involved in mitotic cell cycle] GO:0051443 [positive regulation of ubiquitin-protein transferase activity] GO:0051726 [regulation of cell cycle] GO:0070194 [synaptonemal complex disassembly] GO:0071168 [protein localization to chromatin] GO:0090435 [protein localization to nuclear envelope] GO:0097711 [ciliary basal body docking] GO:1900182 [positive regulation of protein localization to nucleus] GO:1901673 [regulation of mitotic spindle assembly] GO:1902749 [regulation of cell cycle G2/M phase transition] GO:1904668 [positive regulation of ubiquitin protein ligase activity]
The Human Protein Atlas project is funded
MENU
